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Abstract
A recent widespread outbreak of Escherichia coli O104:H4 in Germany demonstrates the dynamic nature of emerging and
re-emerging food-borne pathogens, particularly STECs and related pathogenic E. coli. Rapid genome sequencing and public
availability of these data from the German outbreak strain allowed us to identify an O-antigen-specific bacteriophage tail
spike protein encoded in the genome. We synthesized this gene and fused it to the tail fiber gene of an R-type pyocin, a
phage tail-like bacteriocin, and expressed the novel bacteriocin such that the tail fiber fusion was incorporated into the
bacteriocin structure. The resulting particles have bactericidal activity specifically against E. coli strains that produce the
O104 lipopolysaccharide antigen, including the outbreak strain. This O-antigen tailspike-R-type pyocin strategy provides a
platform to respond rapidly to emerging pathogens upon the availability of the pathogen’s genome sequence.
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Introduction
Shiga toxin producing E. coli (STECs) cause foodborne
outbreaks of hemorrhagic colitis which often leads to hemolytic-
uremic syndrome (HUS) [1]. The highly virulent E. coli O157:H7
has been the most concerning strain in recent years and has been
declared an adulterant in food products [2,3]. However, it has long
been recognized that non-O157 STECs are also prevalent, and six
additional STECs have also recently been declared adulterants
[4]. More recently a very large outbreak in Germany was caused
by a highly virulent enteroaggregative E. coli O104:H4 that
encodes the potent shiga toxin 2, resulting in a high incidence of
HUS [5–10].
R-type pyocins are high molecular weight bacteriocins pro-
duced by some Pseudomonas aeruginosa strains and have bactericidal
activity mainly against other strains within the species, for a review
see [11]. These bacteriocins resemble the contractile tail structures
of phages of the Myoviridae family, particularly the P2-like phages.
Upon binding to a receptor on the target bacterium surface via six
homotrimeric tail fibers, the R-type pyocin structure contracts its
sheath, extending its core to form a channel across the bacterial
envelope. As a consequence, the bacterial membrane potential is
dissipated, resulting in rapid death of the cell [12]. The binding of
a single pyocin particle can kill a bacterium [13]. R-type pyocins
can be retargeted to other bacteria by creating fusions between the
pyocin tail fiber and tail fibers or tail spikes (i.e. receptor binding
proteins) from bacteriophages specific for the target bacteria,
thereby changing the specific interaction near the surface of the
outer membrane [14,15]. One such engineered pyocin, AvR2-
V10, has been retargeted to specifically kill E. coli O157:H7 by
fusing the O-antigen specific tail spike from phage phiV10 to the
R2 pyocin tail fiber. AvR2-V10.3 has been shown to be efficacious
in preventing and treating E. coli O157:H7-induced hemorrhagic
colitis in a rabbit model and represents a new class of targeted
antimicrobials [16].
Here we created an O104-specific R-type pyocin that kills the
highly virulent shiga toxin-producing enteroaggregative E. coli
O104:H4 associated with the 2011 outbreak as well as other E. coli
O104 strains. This was accomplished without any O104 strain in
hand or a donor bacteriophage. From the on-line draft genome
sequence of E. coli O104:H4, we identified a gene encoding an O-
antigen specific P22-like tailspike. This gene was then synthesized
and used to engineer an appropriate pyocin tail fiber fusion gene
that was then expressed and incorporated into the pyocin structure
creating AvR2-104.1. AvR2-104.1 is highly sensitive and specific,
killing all tested E. coli strains that produce the O104 antigen but no
other O-antigen type. Thus, the rapid acquisition and public
availability of the genome sequence allowed us to identify a strategy
to develop a targeted antibacterial to this emerging pathogen.
Results
BLAST search analysis of the draft genome sequence of E. coli
O104:H4 from the German outbreak strain revealed a P22-like
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LB226692. This entire gene was synthesized and then used as a
template to make fusions with the R2 pyocin tail fiber. Two fusions
were made between the first 164 amino acids of the R2 pyocin tail
fiber and amino acids 114–659 or amino acids 118–659 of the E.
coli O104 tail spike. The genes for these two fusions were
separately cloned into plasmid DG100 under transcriptional
control of PTAC and separately transformed into P. aeruginosa
strain PAO1 Dprf15, deleted for the R2 pyocin wild type tail fiber
gene [14,15]. This system is designed such that the tail fiber fusions
supplied in trans complement the tail fiber deletion of the genome-
encoded pyocin gene cluster. Upon induction with IPTG (to
induce the fusions) and mitomycin C (to induce the pyocin gene
cluster), R-type pyocin particles were produced that incorporated
the tail fiber fusions, termed AvR2-O104.1 and AvR2-O104.2.
Both particles were initially tested against E. coli strain RM13368
and were found to have the predicted bactericidal activity. AvR2-
O104.1 was chosen for further characterization. Figure 1A shows
the results of a lawn spot assay of different dilutions of AvR2-
O104.1 against strain RM13368. Clear zones of killing occurred at
the highest concentrations of the pyocin, with zones of clearing
becoming somewhat more opaque with decreasing concentrations
of pyocin. The results of a titration survival assay show multiple log
reductions in bacterial counts with bactericidal activity decreasing
with decreasing pyocin concentration (Figure 2B). Based on the
survival assay, yield from a 200 ml culture was about was about
10
12 killing units (KU).
The bactericidal activity of AvR2-104.1 was evaluated with
multiple E. coli O104 isolates: five O104 strains obtained from
cattle, an O104:H21 clinical outbreak strain, O104:H4 enteroag-
gregative strain (EAEC) 55989, and five strains from four patients
associated with the 2011 German outbreak. All strains that
expressed the O104 antigen were sensitive to AvR2-O104.1
(Table 1). A group of seven non-O104 serotypes was also tested to
evaluate the specificity of the pyocin (Table 2). One E. coli strain,
serotype O9:K9:H12 (ATCC 23505) was also sensitive to AvR-
O104.1, a result consistent with the fact that K9 high molecular
weight polysaccharide capsule is structurally identical to the
repeating sugar subunit of the O104 high molecular weight
lipopolysaccharide (LPS) [17]. However, none of the six other
non-O104 strains of E. coli was sensitive to AvR2-O104.1. It is
noteworthy that an isolate from a culture plate of a stool sample
US patient (‘‘patient 3’’) associated with the German outbreak was
insensitive (Table 2, strain RM15013). However, we determined
subsequently that this isolate is a phenotypic variant compared to
the other German outbreak strains, and similar to ‘‘rough’’ LPS
Figure 1. Bactericidal activity of AvR2-O104.1. A. Lawn spot assay
of a 5-fold dilution series of AvR2-104 showing zones of killing E. coli
strain RM13368. B. Titration survival assay of AvR2-104 on strain
RM13368. 10
8 cells were incubated in individual wells of a multi-well
plate with 5-fold serial dilutions of pyocin (left to right) for a period of
40 minutes. Survivors are then 10-fold serially diluted (top to bottom)
and plated on LB agar to determine the number of surviving colony
forming bacteria. By this assay a typical 200 ml preparation of AvR2-104
yields approximately 10
12 killing units total (see Materials and Methods).
doi:10.1371/journal.pone.0033637.g001
Figure 2. Silver stained SDS-PAGE analysis of LPS extracted from E. coli O104 strains and resistant mutants. See Tables 1 and 2 for
strain details. The pyocin-resistant strains (R) express a highly truncated O-antigen, or O-antigen that have a decreased concentration of the high
molecular weight structure (HMW LPS) compared to the pyocin-sensitive strains (S).
aStrain RM15013 was run in a different gel than the other strains
shown in this panel.
doi:10.1371/journal.pone.0033637.g002
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antigen (Table 2, Figure 2).
Surviving colonies sometimes arise within the zone of clearing in
a bacterial lawn of an R-type pyocin spot assay, and often prove to
be resistant mutants. One or more such isolated colonies were
picked from several of the O104 strains, subcultured, and
subjected to further testing (see Table 2). LPS isolated from those
confirmed to be resistant to AvR2-O104.1 were analyzed by SDS-
PAGE (Figure 2). Visual analysis of the gels revealed that bands
corresponding to the high molecular weight LPS of the mutants
were missing or greatly reduced in intensity indicating that the O-
antigen is either truncated (‘‘rough mutant’’) or the O-antigen
repeat units were present at much lower concentration (Figure 2).
Discussion
We have engineered a novel R-type pyocin, AvR2-O104.1,
which is highly specific and sensitive for E. coli O104. We conclude
that the engineered pyocin utilizes the O104-antigen as a receptor
for the following reasons. (i) Related phage P22-like tail spikes
typically target O-antigens or K antigens. (ii) All of the strains that
produce the O104 antigen were AvR2-O104.1-sensitive, regard-
less of other antigenic determinants expressed. (iii) German
outbreak strain RM15013 expressing a highly truncated O104
LPS (i.e. ‘‘rough mutant’’) was resistant to AvR2-O104.1. (iv)
AvR2-O104.1-resistant mutants selected from other O104 strains
also had truncated O104-antigens. (v) A K9 strain of E. coli
expressing the same repeating structural polysaccharide unit as
O104 also was sensitive to AvR2-O104.1. (vi) E. coli strains
expressing other O-antigen serotypes were not sensitive to AvR2-
O104.1.
In the presence of high concentrations of R-type pyocins,
resistant mutants can be selected. This was noted for the O157-
specific pyocin AvR2-V10.3 [15] and is also the case for AvR2-
104.1. For both pyocins, the dominant resistant phenotype is loss
of high molecular weight O-antigen. Since O-antigens typically
contribute to virulence [18,19] we expect that these resistant
mutants are compromised in virulence and are expected to exhibit
concomitant reduction of pathogenic threat.
The tailspike gene used to create AvR2-O104.1 is likely part of
a prophage remnant in the genome of the German outbreak
strain, since there is a deletion in nearby prophage genes, D-
ROD4 [10]; whereas, in the close relative enteroaggregative
Table 1. E. coli strains sensitive to AvR2-O104.1.
Strain Number Serotype/Serovar Details
a
RM8415 O104 Cow feces, CA, 2009
RM8799 O104 Cow feces, CA, 2009
RM9387 O104 Cow feces, CA, 2009
RM9388 O104 Cow feces, CA, 2009
RM11037 O104 Cow feces, CA, 2010
RM13368 O104:H21 CDC 94-3024; ATCC BAA-178
RM14735 O104:H4 German outbreak, US-MA patient 1
RM15012 O104:H4 German outbreak,US-MI patient 2
RM15014 O104:H4 German outbreak, US-MI patient 3
RM15031 O104:H4 German outbreak, Canada
RM15038 O104:H4 Republic of Georgia, 2009EL-2050,
CDC
RM15039 O104:H4 Republic of Georgia, 2009EL-2071,
CDC
RM15037 O104:H4 Enteroaggregative strain 55989
ATCC 23505 O9:K9(B):H12 NCDC Bi 316-42, human, peritonitis
aSource, year sample collected, other strain designations, and two letter state
abbreviations (CA, California; MA, Massachusetts; MI, Michigan).
doi:10.1371/journal.pone.0033637.t001
Table 2. E. coli strains resistant to AvR2-O104.1.
Strain number Serotype/Serovar Details
RM8297 O26 Cow feces
RM10351 O111 Cow feces
RM2048 O45:H2 DECA 11C, human isolate, hemorrhagic colitis, CDC
RM5704 O145:H28 CDPH:Z11198, human isolate
RM10068 O121 Water trough (ranch)
RM6158 O157:H7 Feral swine feces
ATCC 43895 O157:H7 CDC EDL933, hamburger (outbreak)
RM10744 O103 Cow feces
RM15013 O104:H4 German outbreak, US-MI patient 3, variant PFGE profile (1 band
difference), truncated LPS
RM15155 O104 Resistant mutant of RM8145
RM15156 O104 Resistant mutant of RM8799
RM15157 O104 Resistant mutant of RM9388
RM15158 O104 Resistant mutant of RM11037
RM15159 O104:H21 Resistant mutant of RM13368
RM15160 O104:H4 Resistant mutant of RM14735
RM15161 O104:H4 Resistant mutant of RM15014
RM15162 O104:H4 Resistant mutant of RM15031
doi:10.1371/journal.pone.0033637.t002
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complete prophage. However, it has not been determined whether
this latter locus is capable of producing infectious particles. Phage
P22-like tailspike proteins are responsible for host specificity and
typically bind to O-antigens. These tailspike proteins consist of a
highly conserved N-terminal head-binding domain of about 110
amino acids and a C-terminal O-antigen binding domain that is
divergent [21–22]. Consistent with this structure, the first 113
amino acids of the E. coli O104 tail spike share 79% sequence
identity with that of the phage P22 tailspike, whereas the C-
terminal 546 amino acids share little sequence similarity with
anything in the GenBank database. However, based on the fact
that the C-terminal portion of tail spikes of similar phages are
responsible for receptor binding, we reasoned that the comparable
region of this protein has a similar function. The killing spectrum
of AvR2-O104.1 confirms that this C-terminal domain is in fact
responsible for O-antigen binding.
P22-like prophages typically encode an acetylase gene that
modifies the O-antigen [23–25]; acetylation of the O-antigen of an
O104 strain has been reported previously [26]. Indeed, a putative
O-antigen acetylase gene, EGR74046 (Genbank accession no. A-
FOB02000092), located just downstream of the tailspike gene in
both the German outbreak strain and enteroaggregative O104:H4
strain 55989 could be responsible for this O-antigen acetylation in
both strains. The fact that the acetylase gene is retained in the
prophage remnant of the German outbreak strain in spite of its
losing much of the prophage locus is intriguing and worthy of
determining functional activity, especially considering the hyper-
virulence of the German O104:H4 outbreak strains.
Natural R-type pyocins have been shown in animal models to
be efficacious in treating systemic infections [27–29]. More
recently, the engineered R-type pyocin AvR2-V10.3 specific for
E. coli O157 strains has been demonstrated to be efficacious at
treating E. coli O157:H7 infections in an infant rabbit model [16].
We anticipate that a panel of four to six engineered pyocins
targeting specific STECs associated with the most severe disease
(e.g. HUS), and now including AvR2-O104, will be a valuable tool
for treating these serious infections.
A recent commentary in Nature emphasized the failure of
genomics to advance the development of new treatments for
bacterial diseases [30]. In that context, it is worth noting that the
published draft unassembled genome sequence data from the E.
coli O104:H4 strain responsible for the 2011 German outbreak,
provided rapidly by next generation DNA sequencing technology,
facilitated identification of a strain-specific binding motif in the
form of a tailspike of a presumably defective prophage. This
information led directly to the development of a targeted
bactericidal agent to kill O104-positive E. coli. Thus, this R-type
pyocin platform strategy provides at least one example of the
potential value of a draft sequence for the design and production
of specific bactericidal agents against emerging bacterial pathogens
of humans. A recent BLAST search for P22-like tailspikes shows
that several dozen sequenced E. coli genomes encode P22-like
tailspikes, which could immediately be used to generate specific
pyocins. Furthermore, other phage tail fiber genes have been used
to retarget pyocins [14] and it is likely that nearly every E. coli
genome encodes some prophage or prophage remnant receptor
binding protein. Of note is the speed in which a specific R-type
pyocin can be developed. Upon determination of the genome
sequence of a new pathogen, it would be a matter of weeks to
generate a pyocin by this method; this time could be cut to less




Table 1 shows strains tested for sensitivity to AvR2-O104.1.
Clinical isolates of O104:H4 were kindly provided by: J. Rudrick,
Michigan Dept. of Public Health (RM15012, RM15013,
RM15014); F. Valdes, Ontario Agency for Health Protection
and Promotion (RM15031); L. Connolly, Massachusetts Dept. of
Public Health (RM14735); M. McDaniels, N. Strockbine, E.
Sowers, Centers for Disease Control (RM15038, RM15039); J.
Nataro and F. Ruiz, U. of Maryland (RM15037). All other strains
were obtained from the culture collection maintained by R.
Mandrell at the USDA, ARS, WRRC, Produce Safety and
Microbiology Research Unit, Albany, CA. Patient sources of
strains are anonymous. IRB approval is not required for testing of
clinical bacterial isolates.
Construction of AvR2-104.1 and AvR2-104.2
The entire tailspike gene from the remnant prophage of E. coli
O104:H4 was synthesized by GenScript (Piscataway, NJ). From this
template, PCR primers were designed to create genes encoding
fusions between the C-terminus of the tailspike and the N-terminal
amino acid residues 1–164 of the R2 tail fiber. Plasmid DG100,
which contains the R2-P2 tail fiber fusion under control of PTAC
[14], was digested with EcoR1 and HindIII to excise the C-terminal
portion of the P2 tail fiber. Two separate PCR fragments encoding
aminoacids114–660(primers59-tttcctaagcttcggcaagaattacaggggag-
39 and 59- aaacgacggccagtgaattc -39) or 118–660 (primers 59-
tttcctaagcttcaggggagcgcaggagtcat -39 and 59- aaacgacggccagtgaattc-
39) of the E. coli O104 tail spike were amplified with HindIII and
EcoR1 ends and inserted into the digested DG100 to create DG645
and DG646 respectively. These plasmids were transformed into
PAO1 Dprf15 [14] to create BDG63 and BDG64 respectively.
Expression of AvR2-104.1 and AvR2-104.2
BDG63 and BDG64 were grown at 37uC in trypticase soy broth
supplemented with 100 mg/ml gentamicin to an OD600 of
0.3 cm
21, after which IPTG and mitomycin C were added to
250 mM and 3 mg per ml, respectively. After 5 hours the culture
was visibly lysed (OD600 of ,0.2 cm
21). Large cellular debris was
removed by centrifugation at 60006g for 20 minutes. Finer
cellular debris was removed by centrifugation at 16,0006g for
1 hour. This was followed by a high speed spin at 42,0006g for
1 hour to pellet the pyocin particles. Pyocin in the pellet was
typically resuspended in 10 mM Tris-Cl pH 7.5, 50 mM NaCl at
a volumes of 1/200 to 1/50 of the lysate volume.
Activity assays
Spot killing assays were performed as described previously [14].
Briefly, lawns of target bacteria were prepared by adding 5 ml of
molten tempered LB agar (0.5%) to 200 ml of an overnight culture.
This inoculated overlay agar was poured onto a dry 1.5% LB agar
plate and allowed to set. Aliquots (5 ml) of serial 5-fold dilutions of
pyocin were spotted directly on the top agar and allowed to dry.
After overnight incubation, killing of target bacteria was indicated
by circular zones of clearing in the lawn of bacterial growth.
Titration survival assays were performed also as described
previously [14]. Briefly, dilutions of pyocin are added to a fixed
number of bacteria (1610
9 cfu), incubated for 40 min at 37uC,
then plated to count bacterial survivors. The concentration of
pyocin is measured as individual bactericidal killing units (KU)
which is related to the fraction of survivors in a Poisson
distribution m=2lnS where m is the average number of killing
events per cell and S is the fraction of bacterial survivors.
E. coli 0104-Specific R-Type Pyocin
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LPS was prepared and analyzed by SDS-PAGE by the
following procedure. Bacteria grown on Luria-Bertani agar
overnight were harvested with a 10 ml loop and suspended in
200 ml sterile water in a microfuge tube. A 200 ml sample of freshly
prepared 26 Tricine gel sample buffer (cat. no. 161-0739; Bio-
Rad, Hercules, CA) containing a final concentration of 286 mM
2-mercaptoethanol (Sigma-Aldrich, cat no. M-138, 14.3 M stock)
(TB-ME) was added to each sample, the sample mixtures were
vortexed for 1 minute, then incubated in boiling water for
5 minutes to lyse bacteria. After cooling to room temperature,
10 ml of a 20 mg ml
21solution of Proteinase K (PK) (Roche Inc.;
recombinant Proteinase K) was added and the samples were
incubated in a 60uC water bath for 2 hr to digest proteins in the
lysate. The PK-treated lysates can be used immediately or stored
at 4uC until needed. A 25 ml sample of this sample was transferred
to a new microfuge tube and 75 ml of fresh TB-ME was added and
the samples were heated at 100uC for 2 min. Five ml samples were
added to wells of a 10–20% Tricine gradient gel (Invitrogen, Inc.,
Cat no. EC6625BOX), and the gels were electrophoresed in
Tricine SDS running buffer (Invitrogen Novex, Cat no. LC1675)
in an electrophoresis system (Invitrogen/Life Tech., Novex Xcell
Surelock) for 70 min at 135 constant voltage (BioRad Powerpak
200; Hercules, CA). The gels were treated with sodium
metaperiodate and LPS was silver stained as described previously
[31].
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